IMPACT OF SYNBIOTIC SUPPLEMENTATION WITH EDUCATING LOW-CALORIE DIET ON GLYCAEMIA, ANTHROPOMETRIC INDICES, INFLAMMATORY BIOMARKERS AND HEPATIC ENZYMES IN INDIVIDUALS WITH METABOLIC SYNDROME

Background and Aim: Metabolic syndrome (MetS) is defined as a basis for triggering and developing a myriad of chronic diseases. The current study was conducted to ascertain the effect of synbiotic supplementation with educating low-calorie diet on glycemic and anthropometric indices, inflammatory factors and hepatic enzymes in patients with MetS.Methods: 108 subjects between 25 to 65 years with MetS participated in this double-blind randomized clinical controlled trial. Subjects in Synbiotic group (n=52) were received 1000mg/day synbiotic supplement (Familact®, Zist Takhmir) and individuals in Placebo group were consumed the same amount of standard placebo capsules for 12 weeks. All the participant had been followed a healthy, low-calorie diet.Results: Synbiotic supplementation in subjects with MetS eventuated in a significant decline in fasting blood sugar (FBS) concentration (P=0.007) between two groups post-intervention, and serum glutamate-pyruvate transaminase (SGOT) (P=0.01) and Insulin-glucose-ratio (IGR) (P=0.005) only in Synbiotic group compared with baseline. A moderate non-significant alleviation of insulin, homoeostatic model assessment-insulin resistance (HOMA-IR), homoeostatic model assessment-Beta (HOMA-B), high sensitive C-reactive protein (hs-CRP) in both groups, and serum glutamate-pyruvate transaminase (SGPT) and alkaline phosphatase (ALP) in Synbiotic group in within-the-group analysis nonetheless were detected. Additionally, anthropometric indices including weight, body mass index (BMI) and waist-to-hip-ratio (WHR) showed an inclination to be significant (P<0.001) in both groups compared to baseline.Conclusion: ConclusionTo the nutshell, synbiotic supplementation combined with low-calorie diet indicates some promising effects on glycaemia, hepatic enzymes, inflammatory biomarkers and anthropometric indices in those who suffer from MetS and its comorbidities.